Nine out of ten wound patients receive better triaged care with MolecuLight imaging device

158

MolecuLight Inc., a provider of handheld real-time fluorescence imaging for chronic wounds, has announced the publication of “Fluorescence imaging guided dressing change frequency during negative pressure wound therapy: a case series”: a new paper published today in the Journal of Wound Care.

This case series by Rose Raizman reports on the use of fluorescence imaging in conjunction with routine wound assessments for clinical signs and symptoms of infection in patients undergoing negative pressure wound therapy (NPWT) at Scarborough Health Network, Ontario, Canada.

Real-time information was obtained non-invasively from fluorescence images captured with the MolecuLight i:X. The images assisted in determining the presence or absence of bacterial fluorescence, its location and changes over time. In the study, this information significantly impacted treatment decisions and was used to improve the use of NPWT resources and dressing change frequency.

This study reported that nine out of ten patients were likely to have received less appropriate triaged care without the fluorescence information. Specifically, 60% of patients may have been undertreated for their bacterial burden. These patients therefore benefited from increased resources in the short term, while 30% of patients were being overtreated and fluorescence information prompted a decrease in resource use. Based on microbiological confirmation and wound progress, triaging resources elsewhere did not compromise wound progress.

The study reports on how fluorescence imaging in real-time helped to guide:

  • bacterial burden-based and personalized treatment regimens
  • clinician selection of NPWT with or without instillation of wound cleansers
  • the extent and location of wound cleaning during dressing changes.

Furthermore, the ability to visualize fluorescence emitted from bacteria, prior to the removal of dressings, led to expedited dressing changes when heavy bioburden was detected. It also guided postponement of dressing changes for 24 hours when red fluorescence was not observed, avoiding unnecessary disturbance of the wound bed.

This study also describes the economic benefit of leveraging fluorescence imaging to help guide treatment decisions, along with clinical signs and symptoms, for managing NPWT. The author reports a potential USD$1,552 single patient cost saving due to fluorescence evidence-based treatment plan changes.

The paper concludes: “Fluorescence images acquired in this series of 10 patients provided real-time information on bacterial contamination in wounds. Having access to this information facilitated immediate, evidence-based and patient-specific changes in treatment plans. Images prompted and otherwise helped guide timing of dressing changes, guided the extent of wound cleaning, and guided selection of NPWT therapies that were most appropriate for patient needs.”

LEAVE A REPLY

Please enter your comment!
Please enter your name here